chartexchange

Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic

Small Caps | Nov 11, 2026 10:36 PM EST

Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.

Read original article